RFA
SLDB icon

Reilly Financial Advisors’s Solid Biosciences SLDB Stock Holding History

Reilly Financial Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$0 Hold
13
– – ﹤0.01% 1199
2021
Q3 		$0 Hold
13
– – ﹤0.01% 1036
2021
Q2 		$1K Hold
13
– – ﹤0.01% 972
2021
Q1 		$1K Hold
13
– – ﹤0.01% 997
2020
Q4 		$2K Buy
+13
New +$822 ﹤0.01% 814

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Reilly Financial Advisors's SLDB Position: Q4 2021 in Review

Reilly Financial Advisors held its Solid Biosciences (SLDB) position steady in Q4 2021 at 13 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1199.

Reilly Financial Advisors first reported a position in SLDB in Q4 2020 and has held it in 5 quarters since. The position peaked at $2K in Q4 2020. 82 funds tracked by Wall St. Rank hold SLDB as of Q4 2021.

  • Reilly Financial Advisors held 13 shares of Solid Biosciences worth $0 as of Q4 2021.
  • Reilly Financial Advisors left its Solid Biosciences share count unchanged in Q4 2021.
  • Solid Biosciences made up ﹤0.01% of Reilly Financial Advisors's portfolio in Q4 2021, its #1199 holding.
  • Reilly Financial Advisors first reported a position in Solid Biosciences in Q4 2020 and has held it in 5 quarters since.
  • Reilly Financial Advisors's Solid Biosciences position peaked at $2K in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.